Jessie Xie
Hogan Lovells International LLP
Hogan Lovells International LLP
Client SatisfactionLeveraging its lawyers’ experience as government officials in regulatory and policy agencies, Hogan Lovells International LLP's Greater China life sciences practice is consistently sought out to for complex regulatory issues. The team advises at all stages of life sciences products, from initial clinical trials to off-patent strategy, business development and defence-side litigation The team also advises on new technology-driven areas, such as digital health, AI, gene therapy and regenerative medicine. On the mainland, Lu Zhou advises life sciences and healthcare clients on cross-border transactions; and Calvin Ding represents companies (and their board committees) in relation to corruption, conflicts of interest, trade compliance and cybersecurity incidents. Jessie Xie's practice covers regulatory work and commercial contracts in the pharmaceutical, medical devices, healthcare, food, and cosmetics sectors.
Legal 500 Editorial commentary
Key clients
- Sinopharm Commonwealth Company
- Merck Sharp & Dohme
- Aspen
Work highlights
- Advised Sinopharm Commonwealth Company on making a pre-conditional proposal to privatise China Traditional Chinese Medicine Holdings Co.
- Acted for Merck Sharp & Dohme in cross-border litigation concerning rights to the MERCK trade mark and trade name.
Lawyers
Leading associates
Leading associates with regular involvement in their team's key work, and recognition from peers or clients as being ones to watch.
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Lu Zhou
Hogan Lovells International LLPPractice head
The lawyer(s) leading their teams.
Lu Zhou, Calvin Ding